Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Payables (2018 - 2025)

Neurogene's Payables history spans 6 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Payables rose 46.18% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, up 46.18%, while the annual FY2025 figure was $2.0 million, 46.18% up from the prior year.
  • Payables reached $2.0 million in Q4 2025 per NGNE's latest filing, up from $1.5 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $5.4 million in Q1 2023 to a low of $1.3 million in Q4 2024.
  • Average Payables over 3 years is $2.5 million, with a median of $2.0 million recorded in 2025.
  • Peak YoY movement for Payables: tumbled 71.92% in 2024, then skyrocketed 101.25% in 2025.
  • A 3-year view of Payables shows it stood at $2.6 million in 2023, then plummeted by 48.54% to $1.3 million in 2024, then skyrocketed by 46.18% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Payables are $2.0 million (Q4 2025), $1.5 million (Q3 2025), and $2.1 million (Q2 2025).